EXACT Sciences Co. (EXAS) Given Consensus Rating of “Hold” by Analysts
Shares of EXACT Sciences Co. (NASDAQ:EXAS) have been assigned an average rating of “Hold” from the eighteen ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $51.72.
A number of analysts have recently commented on the stock. BidaskClub lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research lowered shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. Robert W. Baird upgraded shares of EXACT Sciences from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $42.56 to $56.00 in a research note on Tuesday, February 27th. Leerink Swann set a $67.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Benchmark lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd.
In related news, insider Kevin T. Conroy sold 121,849 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.45, for a total transaction of $6,512,829.05. Following the completion of the sale, the insider now directly owns 951,901 shares in the company, valued at $50,879,108.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kevin T. Conroy sold 123,512 shares of the business’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $52.58, for a total transaction of $6,494,260.96. Following the sale, the insider now owns 953,564 shares of the company’s stock, valued at $50,138,395.12. The disclosure for this sale can be found here. Insiders have sold 669,312 shares of company stock valued at $33,558,028 over the last 90 days. 4.00% of the stock is currently owned by company insiders.
EXACT Sciences (NASDAQ:EXAS) traded up $2.07 during trading hours on Wednesday, reaching $47.49. 1,038,664 shares of the company’s stock were exchanged, compared to its average volume of 3,218,801. EXACT Sciences has a 1-year low of $19.91 and a 1-year high of $63.60. The company has a market cap of $5,493.16, a price-to-earnings ratio of -47.65 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.77 and a current ratio of 7.15.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, February 22nd. The medical research company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The firm had revenue of $87.41 million during the quarter, compared to analyst estimates of $87.42 million. During the same period in the previous year, the business posted ($0.34) earnings per share. The business’s revenue for the quarter was up 148.0% on a year-over-year basis. sell-side analysts anticipate that EXACT Sciences will post -0.84 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “EXACT Sciences Co. (EXAS) Given Consensus Rating of “Hold” by Analysts” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/exact-sciences-co-exas-given-consensus-rating-of-hold-by-analysts/1909462.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.